J Korean Ophthalmol Soc > Volume 53(12); 2012 > Article
Journal of the Korean Ophthalmological Society 2012;53(12):1807-1813.
DOI: https://doi.org/10.3341/jkos.2012.53.12.1807    Published online December 15, 2012.
Comparison of Two Doses of IVB and Prognostic Factor on Myopic CNV : 1-Year Outcome.
Eun Hae Lim, Yoon Soo Jang, Young Ju Lew, Su Jin Yoo
Myung-Gok Eye Research Institute, Department of Ophthalmology, Kim's Eye Hospital, Konyang University, Seoul, Korea. yjlew@kimeye.com
근시성 맥락막 신생혈관 환자에서 유리체강내 베바시주맙 주입방법에 따른 효과와 예후인자
임은혜⋅장윤수⋅유영주⋅유수진
Myung-Gok Eye Research Institute, Department of Ophthalmology, Kim’s Eye Hospital, Konyang University, Seoul, Korea
Abstract
PURPOSE
To compare the efficacy of 3 consecutive monthly intravitreal bevacizumab (IVB) injections (fixed regimen group) with a single IVB injection (PRN group) on patients with myopic choroidal neovascularization (CNV) and to determine the prognostic factors associated with IVB injection outcomes. METHODS: 23 Twenty-three eyes in 21 patients with myopic CNV (14 eyes in the fixed regimen group and 9 eyes in the PRN group) treated with IVB were studied retrospectively. Best corrected visual acuity (BCVA), central macular thickness (CMT), the size of CNV prior to the initial IVB injection, CMT at the completion of treatment, and the number of IVB injections during the study period was measured. RESULTS: IVB resulted in improved BCVA and decreased CMT in both groups, and the differences before and after IVB injections were significantly correlated. Average injection time in the fixed regimen group and PRN group was 3.4 +/- 0.9 and 1.5 +/- 0.7 respectively, and was not statistically significant (p = 0.16). Differences between the groups in BCVA (p = 0.83) and CMT (p = 0.38) were not significantly correlated. Among the variables measured prior to IVB injection that affected final BCVA was age (p = 0.01). CONCLUSIONS: In the present study, a single injection of IVB compared to 3 consecutive IVB injections in patients with myopic CNV resulted in similar outcomes. In the future, these results can be considered as a reference when designing treatments for myopic CNV patients.
Key Words: Bevacizumab;Myopic choroidal neovascularization
TOOLS
METRICS Graph View
  • 1 Crossref
  •  0 Scopus
  • 785 View
  • 17 Download
Related articles


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next